Skip to content

Clinical Study on the Treatment of Spleen Deficiency Syndrome's Atopic Dermatitis with Yunpi Huashi Qingfei Decoction and Its Regulation on Bitter Taste Receptor

Clinical Study on the Treatment of Spleen Deficiency Syndrome's Atopic Dermatitis with Yunpi Huashi Qingfei Decoction and Its Regulation on Bitter Taste Receptor

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000143
Enrollment
Unknown
Registered
2024-07-30
Start date
2024-04-25
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Placebo control group:Placebo granule
Yunpi Huashi Qingfei decoction experimental group:Yunpi Huashi Qingfei decoction granule

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Conforming to the Western medicine Williams diagnostic criteria. 2) Conforming to the diagnostic criteria of spleen deficiency syndrome in Traditional Chinese Medicine. 3) The severity of skin lesions belongs to mild to moderate (ESAI = 21 points). 4) Patients' age is above 8 years old and below 60 years old, regardless of gender and ethnicity. 5) Giving informed consent to this clinical project (if the patient is a minor, the consent of the patient and the legal guardian is required), and cooperating with the follow-up and researchers.

Exclusion criteria

Exclusion criteria: 1) Patients with severe internal medicine or surgical diseases; 2) Females who are pregnant or preparing for pregnancy and those in the lactation period; 3) Patients with a history of mental disorders; 4) Patients who have used TCS, TCI and other drugs for treating skin diseases within the recent two weeks; 5) Patients who have used immunosuppressants, antibiotics and biological agents for treatment within the recent two weeks; 6) Patients allergic to any component of the experimental drug.

Design outcomes

Primary

MeasureTime frame
Easi Score;

Secondary

MeasureTime frame
NRS Score;TAS2R38;NOS;TCM syndrome score;NO;

Countries

China

Contacts

Public ContactSong Yu

Longhua Hospital Shanghai University of Traditional Chinese Medicine

sonyui@126.com13501752835

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026